These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Woo SJ; Han JM; Ahn J; Heo JW; Yu HG; Chung H; Song J; Park KU; Park KH Retina; 2012 Apr; 32(4):667-71. PubMed ID: 22307220 [TBL] [Abstract][Full Text] [Related]
43. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Moshfeghi AA Semin Ophthalmol; 2011 May; 26(3):139-48. PubMed ID: 21609227 [TBL] [Abstract][Full Text] [Related]
44. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059 [TBL] [Abstract][Full Text] [Related]
45. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270 [TBL] [Abstract][Full Text] [Related]
46. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121 [TBL] [Abstract][Full Text] [Related]
47. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Gu X; Yu X; Dai H Curr Eye Res; 2014 May; 39(5):518-21. PubMed ID: 24215127 [TBL] [Abstract][Full Text] [Related]
48. All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection. Sundar D; Das T; Chhablani J; Kumar A; Sharma N Indian J Ophthalmol; 2020 Jun; 68(6):1095-1098. PubMed ID: 32461437 [TBL] [Abstract][Full Text] [Related]
49. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542 [TBL] [Abstract][Full Text] [Related]
50. Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection. Lad EM; Maltenfort MG; Leng T Ophthalmic Surg Lasers Imaging; 2012; 43(2):115-20. PubMed ID: 22283227 [TBL] [Abstract][Full Text] [Related]
52. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Falavarjani KG; Modarres M; Hashemi M; Parvaresh MM; Naseripour M; Zare-Moghaddam A; Nekoozadeh S Retina; 2013 May; 33(5):971-4. PubMed ID: 23400076 [TBL] [Abstract][Full Text] [Related]
53. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections. Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476 [TBL] [Abstract][Full Text] [Related]